- Home >
- About Us
Our History
CorMedix Therapeutics’ history reflects the evolution of a small, clinical-stage biotech into a commercial-stage pharmaceutical company focused on combating life‑threatening infections. Founded with the goal of addressing unmet needs in infectious disease, the company initially concentrated on developing an innovative anti‑infective renal therapy that could improve patient outcomes. Today, CorMedix Therapeutics continues to build on this foundation.
CorMedix is Founded
Focused on developing and commercializing therapeutic products for life-threatening diseases and conditions.
NYSE American Listing
CorMedix goes public on the NYSE American, marking a new chapter in the company’s growth.
LOCK-IT-100 Completed
CorMedix completes the LOCK-IT-100 trial, generating pivotal clinical evidence.
NASDAQ Global Market
CorMedix changes its listing to the NASDAQ Global Market, reflecting continued momentum and strategic growth.
FDA Approval
CorMedix receives its first FDA approval.
Commercial Launch
CorMedix successfully launches its first product.
CorMedix Achieves Profitability
CorMedix profitability driven by the successful commercial launch.
Melinta Acquisition
CorMedix acquires Melinta Therapeutics and rebrands as CorMedix Therapeutics, expanding its anti-infective portfolio.